Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.2.162

Efficacy and safety of oxcarbazepine in epileptic children  

Shin, Hye Kyung (Korea University College of Medicine)
Lee, Yoon (Korea University College of Medicine)
Lee, Jee-Yeon (Department of Pediatrics, Kwangmyung-Sungae Hospital)
Choi, Wooksun (Korea University College of Medicine)
Eun, So-Hee (Korea University College of Medicine)
Eun, Baik-Lin (Korea University College of Medicine)
Hong, Young Sook (Korea University College of Medicine)
Lee, Joo Won (Korea University College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.2, 2008 , pp. 162-169 More about this Journal
Abstract
Purpose : Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience. Methods : The patients, who had visited the pediatric neurology clinic of Korea University Guro Hospital from January 2001 to December 2006, were included. The data of 144 patients who were administrated OXC as monotherapy or polytherapy, was summarized retrospectively and we evaluated the efficacy and safety of OXC. Results : After 6 months of OXC therapy, 77 patients (53.5%, n=144) achieved seizure freedom, 48 patients (33.3%) experienced >50% improvement. After 12 months of OXC therapy, cessation of seizure was observed in 88 patients (61.1%, n=133), and 27 patients (18.8%) manifested an improvement. Monotherapy group showed superior efficacy to polytherapy one. The frequent side effects of OXC were drowsiness (20.1%), headache (12.5%), dizziness (9.7%) and rash (8.3%). They did not related to patient's age or sex, and dosage of OXC. Twenty four patients (16.7%) experienced hyponatremia, but which were neither symptomatic nor significant one. Conclusion : The efficacy and safety of OXC in our patients were excellent and had less significant side effects than established international one. We expect this report contributes toward OXC therapy in epileptic children.
Keywords
Oxcarbazepine; Efficacy; Safety; Child;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995;29:341-69   DOI   ScienceOn
2 Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680-700   DOI   ScienceOn
3 Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35:1217-20   DOI   ScienceOn
4 Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680-700   DOI   ScienceOn
5 Knight AK, Cunningham-Rundles C. Oxcarbazepine-induced immunoglobulin deficiency. Clin Diagn Lab Immunol 2005;12:560-1
6 Lofgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojarvi JI. Oxcarbazepine and carbamazepine: expected and unexpected differences and similarities. Epilepsy Curr 2007;7:74-6   DOI   ScienceOn
7 Bulau P, Paar WD, von Unruh GE. Pharmacokintics of oxcarbazepine and lo-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988;34:311-3   DOI
8 Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993;34:163-5   DOI   ScienceOn
9 Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001;15:137-63   DOI   ScienceOn
10 Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine induced hyponatremia, a cross-sectional study. Epilepsy Res 1988;2:269-71   DOI   ScienceOn
11 Grikiniene J, Volbekas V, Stakisaitis D. Gender differences of sodium metabolism and hyponatremia as an adverse drug effect. Medicina 2004;40:935-42
12 Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. Action of GP47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995;36:997-1002   DOI   ScienceOn
13 Calamaras MR, Stowe ZN, Newport DJ Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 2007;27:217-8   DOI   ScienceOn
14 Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006;35:177-81   DOI   ScienceOn
15 Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002;51:613-20   DOI   ScienceOn
16 Wamil AW, Schmutz M, Portet C, Feldmann KF, McLean MJ. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994;271:301-8   DOI   ScienceOn
17 Horga JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006;42:95-113
18 Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-8   DOI   ScienceOn
19 Holtmann M, Krause M, Opp J, Tokarzewski M, Korn-Merker E, Boenigk HE. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Neuropediatrics 2002;33:298-300   DOI   ScienceOn
20 Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007;10:105-10   DOI   ScienceOn
21 Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160-2
22 Rogvi-Hansen B, Gram L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol Ther 1995;68:425-34   DOI   ScienceOn
23 Kloster R, Borresen HC, Hoff-Olsen P. Sudden death in two patients with epilepsy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Seizure 1998;7:419-20   DOI   ScienceOn
24 Sachdeo R, Edward K, Hasegawa H. Safety and efficacyof oxcarbazepine 1200 mg/day in patients with recent onset partial epilepsy. Neurology 1999;52:391
25 Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-80   DOI   ScienceOn
26 Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y, et al. Oxcarbazepine Cognitive Study Group. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006;67:679-82   DOI   ScienceOn
27 Benbadis SR. Tatum WO 4th Advances in the treatment of epilepsy. Am Fam Physician 2001;64:91-8
28 Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol 2006;35:235-9   DOI   ScienceOn
29 Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 2004;3:1-8   DOI   ScienceOn
30 Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Oxcarbazepine in the treatment of epilepsy. Fortschr Neurol Psychiatr 2007;75:100-6   DOI   ScienceOn
31 Arieff AI, Ayus JC, Fraser CL. Hyponatraemia and deathor permanent brain damage in healthy children. Br Med J 1992;304:1218-22   DOI   ScienceOn
32 Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-5   DOI   ScienceOn
33 Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992;11:199-203   DOI   ScienceOn
34 Franzoni E, Marchiani V, Cecconi I, Moscano FC, Gualandi S, Garone C, et al. Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. Eur J Neurol 2006;13:1389-91   DOI   ScienceOn
35 Gram L. Clinical experience with oxcarbazepine. Epilepsia 1994;35 Suppl 3:S21-2
36 Johannessen AC, Nielsen OA. Hyponatremia induced by oxcarbazepine. Epilepsy Res 1987;1155-6
37 Mahmud J, Mathews M, Verma S, Basil B. Oxcarbazepine-induced thrombocytopenia. Psychosomatics 2006;47:73-4   DOI   ScienceOn
38 Palmieri A. Oxcarbazepine-induced headache. Cephalalgia 2007;27:91-3   DOI   ScienceOn
39 Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000;1:396-405   DOI   ScienceOn
40 Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284-9   DOI   ScienceOn
41 Dickinson RG, Hooper WD, Pendlebury SC, Moses D, Eadie MJ. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine. Clin Exp Neurol 1988;25:127-33
42 Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976-8   DOI   ScienceOn
43 Rai PV. Clinical trial for the estimation of anticonvulsive properties and side reactions of a new drug ketocarbamazepine. 10th Epilepsy Int. Symp.; 1978 SEP 10-14; Vancouver. Brussels, Belgium and Connecticut, USA: International League Against Epilepsy, 1978
44 Horga JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006;42:95-113
45 Brewenton TD, Jackson CW. Prophylaxis of carbamezepineinduced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 1994;55:249-51
46 Houtkooper MA, Lammertsma A, Meyer JW, Goedhart DM, Meinardi H, van Oorschot CA, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8   DOI   ScienceOn
47 Lee SA, Lee SK, Kang JK. Hyponatremia associated with oxcarbazepine: cross-sectional study. J Korean Neurol Assoc 2001;19:139-42
48 Martinez W, Ingenito A, Blakeslee M, Barkley GL, McCague K, D'Souza J. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006;9:448-56   DOI   ScienceOn
49 Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients wtih newly, diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6   DOI   ScienceOn
50 Franzoni E, Garone C, Sarajlija J, Gualandi S, Malaspina E, Cecconi I, et al. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report. Seizure 2006;15:292-8   DOI   ScienceOn
51 Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;6:489-501
52 Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006;19:175-80
53 Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics:a review. Pain Pract 2004;4:194-203   DOI   ScienceOn
54 JG Larkin, PJ McKee, G Forrest, GH Beastall, BK Park, JI Lowrie, et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:657-1   DOI
55 Steinhoff BJ, Stoll KD, Stodieck SR, Paulus W. Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res 1992;11:67-70   DOI   ScienceOn
56 Gilham RA, Williams N, Wiedmann K. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg 1988;51:929-33   DOI
57 Hooper WD, Dickinson RG, Dunstan PR, Pendlebury SC, Eadie MJ. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. Clin Exp Neurol 1987;24:105-12
58 Friis ML, Kristensen 0. Boas J, Dalby M, Deth SH, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol 1993;87:224-7
59 Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9   DOI   ScienceOn
60 Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994;35:1419